Drug Trial Radar · NCT01377285
Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD)
Last checked: Nov 20, 2026Latest source record: Oct 14, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
350
Planned (sponsor's estimate)
Start
Jun 2010
Primary completion
Dec 2018
Study completion Dec 2018
Sponsor
- Lead sponsor
- National Taiwan University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Far Eastern Memorial Hospital; Mackay Memorial Hospital; Taipei Medical University Hospital; Shin Kong Wu Ho-Su Memorial Hospital; Cathay General Hospital
- First posted
- Jun 21, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial to investigate the renoprotective efficacy of combined pentoxifylline (PTX) and angiotensin receptor blockers (valsartan), compared with placebo and valsartan in 700 patients with Chronic Kidney Disease (CKD) stages 3 and 4. The effect on cardiovascular comorbidity will also be observed. The observation period will be 3 years. The primary endpoints consists of doubling of serum creatinine, end stage renal disease (ESRD), and death from any cause. The secondary endpoints include changes of microalbuminuria or proteinuria, serum and urinary levels of TNF-a(tumor necrosis factor-alpha ), MCP-1(monocyte chemotactic protein), TGF-beta1(transforming growth factor ), collagens III (amino terminal peptide of procollagen III) and IV, and fibronectin, urinary N-acetyl-beta-glucosaminidase, as well as serum fibrinogen and high-sensitive CRP(C reactive protein), and development of heart failure, nonfatal myocardial infarction, and stroke or transient ischemic attack.
Conditions
- Chronic Renal Failure
Interventions
ARBDrug
Angiotensin II receptor antagonists ,these medicines have names that end in "sartan".For examples:losartan,candesartan,irbesartan,olmesartan,telmisartan,valsartan
PentoxifyllineDrug
This medication is used to improve the symptoms of a certain blood flow problem in the legs/arms (intermittent claudication due to occlusive artery disease)
Placebo (for Pentoxifylline)Drug
Sugar pill manufactured to mimic Pentoxifylline 400mg tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- doubling of serum creatinine, ESRD, and death from any causeTime frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.